Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Debt to Equity: 2021-2022

Historic Debt to Equity for Cardiol Therapeutics (CRDL) over the last 1 years, with Sep 2022 value amounting to $0.01.

  • Cardiol Therapeutics' Debt to Equity was N/A to $0.01 in Q3 2022 from the same period last year, while for Dec 2021 it was $0.09, marking a year-over-year change of. This contributed to the annual value of $0.09 for FY2021, which is N/A change from last year.
  • Latest data reveals that Cardiol Therapeutics reported Debt to Equity of $0.01 as of Q3 2022, which was down 48.37% from $0.03 recorded in Q2 2022.
  • Over the past 5 years, Cardiol Therapeutics' Debt to Equity peaked at $0.09 during Q4 2021, and registered a low of $0.00 during Q1 2022.
  • For the 2-year period, Cardiol Therapeutics' Debt to Equity averaged around $0.03, with its median value being $0.02 (2022).